BiotechTube

GS-248 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Systemic Sclerosis

Conditions

Systemic Sclerosis

Trial Timeline

Dec 29, 2020 → Jun 15, 2022

NCT ID
NCT04744207

About GS-248 + Placebo

GS-248 + Placebo is a phase 2 stage product being developed by Gesynta Pharma for Systemic Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04744207. Target conditions include Systemic Sclerosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT04744207Phase 2Completed
NCT04036227Phase 1Completed

Competing Products

20 competing products in Systemic Sclerosis

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2
52
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
DS-7011a + PlaceboDaiichi SankyoPhase 1
33
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
41
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPhase 2
52
E6742EisaiPhase 1/2
41
KHK4827Kyowa KirinPhase 1
33
KHK4827 + PlaceboKyowa KirinPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + CyclophosphamideEli LillyApproved
85
Baricitinib + PlaceboEli LillyPhase 3
77
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 2
52
LY2127399 + PlaceboEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 1
33

Other Products from Gesynta Pharma

Vipoglanstat + PlaceboPhase 2
44
Formulation A GS-248 + Formulation B GS-248Phase 1
25
GS-248 + PlaceboPhase 1
25